# A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

> **NCT00317200** · PHASE2 · COMPLETED · sponsor: **Hoosier Cancer Research Network** · enrollment: 34 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00317200
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2011-05-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317200, "A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00317200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*